Heiner Glombik

USPTO Granted Patents = 75 (Patent Applications = 7)

EPO Patents = 20 (Patent Applications = 9)

Average Co-Inventor Count = 5.6

ph-index = 21

Forward Citations = 1,201(Granted Patents)

Forward Citations (Not Self Cited) = 1,091(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Hofheim/Ts., DE (1996)
Hofheim am Taunus, DE (1990 - 1997)
Hofheim, DE (1995 - 2012)
Frankfurt-am-Main, DE (2009 - 2019)

Company Filing History:

34 out of 1,827

Sanofi-a Ventis Deutschland Gmbh

patents

22 out of 330

Aventis Pharma Deutschland, Gmbh

patents

12 out of 6,662

Hoechst Aktiengesellschaft

Hoechst Marion Roussel Deutschland Gmbh

Years Active: 1990-2019

Loading Chart...

75 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10392366 - Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2019-08-27),

2. 9908868 - Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-03-06),

3. 9896434 - Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-02-20),

4. 9758520 - Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2017-09-12),

5. 8853412 - Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2014-10-07),

6. 8106023 - 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof (2012-01-31),

7. 8101583 - 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof (2012-01-24),

8. 8048901 - 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals (2011-11-01),

9. 7956085 - 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof (2011-06-07),

10. 7956077 - 2-{-3,'2-(phenyl)-oxazol-4-ylmethoxyl-cyclohexyl methoxy}-propionic acid derivatives used as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes (2011-06-07),

11. 7923468 - 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof (2011-04-12),

12. 7872034 - Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals (2011-01-18),

13. 7820804 - Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof (2010-10-26),

14. 7772429 - Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use (2010-08-10),

15. 7732471 - 6-oxazol-4-ylmetholmethoxy-alko-alkoxymethyl substituted benzoic acid derivatives forming peroxisome proliferator—activated receptor (PPAR) ligands, process for their preparation and methods of use thereof (2010-06-08),

Title: Heiner Glombik: Innovator in Pharmaceutical Solutions

Introduction

Heiner Glombik is a prominent inventor based in Hofheim, Germany, with an impressive portfolio of 75 patents. His groundbreaking work primarily focuses on the development of pharmaceutical compounds aimed at treating various metabolic disorders.

Latest Patents

Among Glombik’s recent innovations are two notable patents concerning azetidine and isoindolinone compounds. The first patent details azetidine compounds that act as GPR119 modulators, intended for the prevention and treatment of diabetes, obesity, dyslipidemia, and related disorders. These compounds present a promising avenue for improving metabolic health and potentially changing treatment paradigms. The second patent highlights isoindolinone compounds, also functioning as GPR119 modulators for similar health applications, reaffirming Glombik’s dedication to addressing critical health challenges with novel chemical solutions.

Career Highlights

Glombik has made significant contributions to the pharmaceutical industry, having worked with reputable companies such as Sanofi-Aventis Deutschland GmbH and Aventis Pharma Deutschland GmbH. His extensive career reflects a commitment to research and development, driving forward innovations that hold the promise of improving patient outcomes in metabolic health.

Collaborations

Throughout his career, Glombik has collaborated with various notable individuals, including Wendelin Frick and Werner Kramer. These partnerships have enabled a fusion of ideas and expertise that have contributed to the successful development of his patented inventions.

Conclusion

Heiner Glombik's contributions to pharmaceutical research underscore his role as an innovative inventor in the field. With a robust portfolio of patents focusing on impactful health solutions, his work continues to pave the way for advancements in treating diabetes, obesity, and related metabolic disorders. Glombik exemplifies the spirit of innovation that drives the pharmaceutical industry forward.

This text is generated by artificial intelligence and may not be accurate.